Michael Ackermann is the founder of Tarsus Pharmaceuticals. Tarsus Pharmaceuticals has raised $260M in total funding. Latest round: IPO. Backed by Pharmakon.
Michael Ackermann is a drug researcher and developer at Tarsus Pharmaceuticals, recognized as an Elite 2021 Drug Researcher. He was involved in the development of TP-03, a drug which achieved collarette cure and mite eradication in Phase 2 trials and received FDA approval in July 2023.
Full founder directory · Investor directory · Company funding database · Fundraising library